Researchers from China Pharmaceutical University have disclosed the discovery and preclinical evaluation of a new receptor-interacting serine/threonine-protein kinase 2 (RIPK2) inhibitor, Zharp2-1, as a potential therapeutic candidate for the treatment of inflammatory bowel disease (IBD).